Patents Assigned to Atlas Antibodies AB
-
Patent number: 9701741Abstract: The present disclosure relates, in one of its aspects, to a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: a) evaluating an amount of RBM3 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.Type: GrantFiled: May 11, 2012Date of Patent: July 11, 2017Assignee: Atlas Antibodies ABInventors: Jakob Eberhard, Karin Jirström
-
Patent number: 9416176Abstract: The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.Type: GrantFiled: April 9, 2014Date of Patent: August 16, 2016Assignee: Atlas Antibodies ABInventors: Mathias Uhlen, Fredrik Ponten, Karin Jirstrom
-
Patent number: 9354232Abstract: There is provided a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the second group is worse than the prognosis of subjects of the first group, comprising the steps of: a) evaluating an amount of PODXL in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the first group.Type: GrantFiled: December 11, 2013Date of Patent: May 31, 2016Assignee: Atlas Antibodies ABInventor: Karin Jirstrom
-
Publication number: 20160054324Abstract: There is provided a method for determining whether a mammalian subject having an endometrial cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of ASRGL1 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.Type: ApplicationFiled: April 4, 2014Publication date: February 25, 2016Applicant: ATLAS ANTIBODIES ABInventors: Per-Henrik Edqvist, Fredrik Ponten
-
Patent number: 9063149Abstract: This invention relates to a method of determining the absolute amount of a target polypeptide in a sample using mass spectrometry.Type: GrantFiled: April 4, 2012Date of Patent: June 23, 2015Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., ATLAS ANTIBODIES ABInventors: Matthias Mann, Marlis Zeiler, Mathias Uhlen, Emma Lundberg, Werner Lothar Straube
-
Patent number: 8999656Abstract: The present disclosure provides a method for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of PODXL protein in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount; b) comparing said sample value from step a) with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to said second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to said first group. Related uses, means and a method of treatment are also provided.Type: GrantFiled: April 26, 2012Date of Patent: April 7, 2015Assignee: Atlas Antibodies ABInventors: Karin Jirström, Mathias Uhlén, Fredrik Pontén
-
Patent number: 8945832Abstract: The present invention provides a method for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment, comprising the steps of: providing a sample earlier obtained from said subject; evaluating the amount of HMGCR protein or HMGCR mRNA present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value obtained in step b) with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. Further, a corresponding method of treatment is provided as well as further methods uses and means which may be employed in connection with breast cancer treatment or treatment prediction.Type: GrantFiled: November 16, 2010Date of Patent: February 3, 2015Assignee: Atlas Antibodies ABInventors: Mathias Uhlen, Fredrik Ponten, Karin Jirström, Donal J. Brennan
-
Publication number: 20140295462Abstract: The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.Type: ApplicationFiled: April 9, 2014Publication date: October 2, 2014Applicant: Atlas Antibodies ABInventors: Mathias Uhlen, Fredrik Ponten, Karin Jirstrom
-
Publication number: 20140221507Abstract: There is provided a method of determining whether a subject belongs to a first or a second group of subjects, wherein the risk of having or developing of a renal impairment is higher in the first group than in the second group, comprising the steps of: a) measuring an amount of fibulin 1 in a sample from the subject to obtain a sample value; b) comparing the sample value to a reference value; and if the sample value is higher than the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is lower than the reference value, c2) concluding that the subject belongs to the second group, wherein the sample is an optionally modified sample derived from urine or blood, such as an optionally diluted serum or plasma sample. Associated means are also provided.Type: ApplicationFiled: July 2, 2012Publication date: August 7, 2014Applicant: Atlas Antibodies ABInventors: Jochen Schwenk, Peter Nilsson, Mathias Uhlén
-
Publication number: 20140170676Abstract: The present disclosure relates, in one of its aspects, to a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: a) evaluating an amount of RBM3 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.Type: ApplicationFiled: May 11, 2012Publication date: June 19, 2014Applicant: Atlas Antibodies ABInventors: Jakob Eberhard, Karin Jirström
-
Patent number: 8747910Abstract: Method for determining whether a mammalian subject having a cancer belongs to a first or a second group, wherein subjects of the first group are more likely to respond to a platinum-based therapy than subjects of the second group, comprising the steps of: evaluating the amount of RBM3 protein or RBM3 mRNA present in at least part of a sample earlier obtained from said subject, and determining a sample value corresponding to said amount; comparing the sample value with a reference value; and, if said sample value is higher than said reference value, concluding that said subject belongs to a first group; and if said sample value is lower than or equal to said reference value, concluding that said subject belongs to a second group. There is further provided means useful in the establishment of a treatment prediction.Type: GrantFiled: February 16, 2010Date of Patent: June 10, 2014Assignee: Atlas Antibodies ABInventors: Karin Jirström, Jakob Eberhard
-
Patent number: 8728739Abstract: The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.Type: GrantFiled: August 16, 2011Date of Patent: May 20, 2014Assignee: Atlas Antibodies ABInventors: Mathias Uhlén, Fredrik Pontén, Karin Jirström
-
Publication number: 20140072991Abstract: The present invention provides a method of determining the absolute amount of a target polypeptide in a sample, said method comprising the following steps: (a) adding (aa) a fusion polypeptide to said sample, said fusion polypeptide comprising (i) at least one tag sequence and (ii) a subsequence of the target polypeptide; and (ab) a known absolute amount of a tag polypeptide comprising or consisting of said tag sequence according to (aa) to said sample, wherein said fusion polypeptide on the one hand is mass-altered as compared to said target polypeptide and said tag polypeptide on the other hand, for example, said fusion polypeptide on the one hand and said target polypeptide and said tag polypeptide on the other hand are differently isotope labeled; (b) performing proteolytic digestion of the mixture obtained in step (a); (c) subjecting the result of proteolytic digestion of step (b), optionally after chromatography, to mass spectrometric analysis; and (d) determining the absolute amount of said target polyType: ApplicationFiled: April 4, 2012Publication date: March 13, 2014Applicants: ATLAS ANTIBODIES AB, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Matthias Mann, Marlis Zeiler, Mathias Uhlen, Emma Lundberg, Werner Straube
-
Patent number: 8632984Abstract: A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.Type: GrantFiled: December 17, 2009Date of Patent: January 21, 2014Assignee: Atlas Antibodies ABInventors: Mathias Uhlen, Fredrik Ponten, Karin Jirstrom
-
Patent number: 8465934Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.Type: GrantFiled: July 6, 2012Date of Patent: June 18, 2013Assignee: Atlas Antibodies ABInventors: Mathias Uhlén, Fredrik Pontén
-
Patent number: 8420788Abstract: The present invention relates to an affinity ligand capable of selective interaction with an epitope sequence consisting of 47 amino acids or less and comprising the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2. Further, it relates to a polypeptide consisting of the epitope sequence and to uses of the affinity ligand and the polypeptide.Type: GrantFiled: October 6, 2009Date of Patent: April 16, 2013Assignee: Atlas Antibodies ABInventors: Karin Jirsrtöm, Fredrik Pontén, Mathias Uhlén
-
Publication number: 20120269764Abstract: A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.Type: ApplicationFiled: December 17, 2009Publication date: October 25, 2012Applicant: Atlas Antibodies ABInventors: Mathias Uhlen, Fredrik Ponten, Karin Jirstrom
-
Patent number: 8241859Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.Type: GrantFiled: October 21, 2011Date of Patent: August 14, 2012Assignee: Atlas Antibodies ABInventors: Mathias Uhlén, Fredrik Pontén
-
Publication number: 20120178108Abstract: In the present disclosure, there is provided a method for improving the immunodetectability of at least one protein in an optionally diluted sample of blood, serum or plasma, comprising a step of heating the sample to a temperature of 64-85° C. prior to a contact between the sample and at least one affinity ligand for detection and/or quantification of the at least one protein.Type: ApplicationFiled: June 26, 2009Publication date: July 12, 2012Applicant: ATLAS ANTIBODIES ABInventors: Mathias Uhlén, Jochen Schwenk
-
Patent number: 8067190Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.Type: GrantFiled: June 4, 2007Date of Patent: November 29, 2011Assignee: Atlas Antibodies ABInventors: Mathias Uhlén, Fredrik Pontén